Sonova stock holds firm as FY 2025 sales reached CHF 3.87 billion

Sonova (CH0012549785) stock is anchored by FY 2025 sales of CHF 3.87 billion and EBIT of CHF 768.7 million, both reported in the companys annual results for the year ended 31 March 2025. The shares closed at CHF 251.20 on 27 July 2026 on SIX, giving the market a current valuation backdrop while investors wait for the next reporting step.

FY 2025 sales at CHF 3.87 billion

Sonova reported FY 2025 sales of CHF 3.87 billion, up 7.4% in local currencies and 6.6% in Swiss francs versus the prior year. EBIT reached CHF 768.7 million, with an EBIT margin of 19.9%, which shows that profitability remained close to one-fifth of revenue even as the group expanded.

Net income came in at CHF 547.3 million for FY 2025, compared with CHF 492.7 million a year earlier, a rise of 11.1%. Basic earnings per share increased to CHF 8.17 from CHF 7.36, an 11.0% improvement that matters for a company whose valuation still depends on sustained margin discipline.

Margin stays near 20%

For a hearing-care group, the key metric is not just growth but the quality of that growth. Sonovas FY 2025 EBIT margin of 19.9% and net margin implied by CHF 547.3 million in net income against CHF 3.87 billion in sales suggest a business that converted revenue into profit at a steady rate.

The company also said it entered FY 2026 with a product pipeline centered on hearing aids and connected devices, and that matters because upgrades in premium segments typically support both sales mix and margin. In investor terms, the combination of CHF 3.87 billion in sales, CHF 768.7 million in EBIT, and CHF 547.3 million in net income gives the stock more than just a story about hearing technology.

Product pipeline matters

Sonova’s product portfolio includes hearing aids under the Phonak brand, one of its most visible consumer-facing names. In FY 2025, the company’s reported revenue base and profit line showed that the core hearing-aid franchise remained the main earnings engine, rather than a side business.

That product mix helps explain why the market tends to focus on the next launch cycle, fit-for-life device upgrades, and the pace at which premium hearing devices convert into revenue. When a company reports CHF 3.87 billion in sales and CHF 768.7 million in EBIT, investors usually watch whether product momentum can keep those numbers moving in the same direction.

Shares at CHF 251.20

Sonova stock closed at CHF 251.20 on 27 July 2026 on SIX, a level that provides the market reference point for the latest trading view. Against FY 2025 revenue of CHF 3.87 billion and EBIT of CHF 768.7 million, the share price reflects a business that still trades on earnings quality as much as on headline growth.

For the next leg, the central question is whether Sonova can extend the 7.4% local-currency sales growth and the 19.9% EBIT margin into FY 2026. The reported numbers leave that debate focused on execution rather than on the basic scale of the company.

Fact box